Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:43 2025-02-07 am EST			5-day change	1st Jan Change
96.83 ^CHF	-0.90%		+1.31%	+9.17%

Feb. 06	AlphaValue/Baader Europe: Novartis Shares 'Hold More Value' After Strong FY24	MT
Feb. 06	NOVARTIS AG : Goldman Sachs gives a Neutral rating	ZD

Novartis Entresto(R) US patent upheld by US Court of Appeals

January 13, 2025 at 01:15 am EST

(MORE TO FOLLOW) Dow Jones Newswires

January 13, 2025 01:15 ET (06:15 GMT)

Latest news about Novartis AG

AlphaValue/Baader Europe: Novartis Shares 'Hold More Value' After Strong FY24	Feb. 06	MT
NOVARTIS AG : Goldman Sachs gives a Neutral rating	Feb. 06	ZD
NOVARTIS : 2024 ended on a strong note; 2025 outlook surpassed expectations	Feb. 05
AstraZeneca shareholders say they need clarity on China investigations	Feb. 05	RE
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 04	MT
Correction: --Novartis on Lookout for Next-Generation Obesity Drug Candidates, The Wall Street Journal Reports	Feb. 04	MT
Novartis on Lookout for Next-Generation Obesity Drug Candidates	Feb. 04	MT
Deutsche Bank Upgrades Novartis to Buy, Lifts PT	Feb. 04	MT
NOVARTIS AG : Deutsche Bank gives a Buy rating	Feb. 04	ZD
Barclays Lifts Novartis' Price Target on Strong FY25 Guidance	Feb. 04	MT
NOVARTIS AG : Deutsche Bank reaffirms its Neutral rating	Feb. 03	ZD
NOVARTIS AG : Buy rating from DZ Bank	Feb. 03	ZD
NOVARTIS AG : UBS remains its Buy rating	Feb. 03	ZD
NOVARTIS : UBS reiterates its recommendation on the stock	Feb. 03	CF
India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise	Feb. 03	RE
Health Care Down Amid Strong Earnings -- Health Care Roundup	Jan. 31	DJ
Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed	Jan. 31	MT
Swiss Equities Close Little Changed as US Inflation Takes Spotlight	Jan. 31	MT
Novartis CEO says U.S. exit from global health programmes to affect millions	Jan. 31	RE
Fed's Preferred Inflation Gauge in Focus, Driving Premarket Gains for US Equity Futures	Jan. 31	MT
Trump's tariff tornado threatens tranquil trade	Jan. 31
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday in Anticipation of Upcoming Economic Data	Jan. 31	MT
Novartis AG, Q4 2024 Earnings Call, Jan 31, 2025	Jan. 31
NOVARTIS AG : Goldman Sachs reiterates its Neutral rating	Jan. 31	ZD
Europe: Stock markets continue to welcome rate cuts	Jan. 31	CF

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

2025-03-03 - TD Cowen Healthcare Conference

More about the company